Summary
The product CJC-1295 DAC 2 mg, manufactured by Biogenix Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number Unknown, was submitted by the reseller biogenixpharma and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of CJC-1295 (mod GRF 1-29), with a concentration of 3.98 mg, 99% above the labeled claim of 2 mg. The product’s purity was determined to be 98.929%.
The testing process began on 11 August 2024, with the sample received on 22 August 2024, and analysis completed on 23 August 2024. While the results confirm high purity, the significantly higher-than-labeled concentration raises concerns about dosage accuracy and consistency. Scrutiny of reseller-submitted samples remains essential to ensure reliability. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Biogenix Pharma
- Product Name: CJC-1295 DAC 2 mg
- Active Ingredient: CJC-1295 (mod GRF 1-29)
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #47811
- Testing Ordered: 11 August 2024
- Sample Received: 22 August 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: biogenixpharma (Reseller)
- Analysis Paid For By: biogenixpharma
Testing Results
- Specification: 2 mg (as stated on the label)
- Measured Concentration: 3.98 mg
- Accuracy: 199% (99% above the label claim)
- Purity: 98.929%
Verification Details
- Verification URL: https://janoshik.com/tests/47811_A92IRL34VIHH
Evaluation of Reseller-Submitted Testing
This analysis highlights the high purity of the tested product but also raises concerns due to its extreme overdosing. Since the reseller biogenixpharma submitted and funded the test, careful evaluation is needed to assess product consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple samples.
Conclusion
The analysis confirms that CJC-1295 DAC 2 mg is highly overdosed, with a measured concentration of 3.98 mg, and maintains an exceptionally high purity of 98.929%. While this batch exhibits strong quality control in terms of purity, the significant deviation in dosage underscores the importance of further testing to ensure accurate labeling and consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding peptide products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
